These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 23885190)

  • 1. Time and Costs of Insulin Treatment in the Care of Newly Registered Type 2 Diabetes Patients in Diabetes Clinics Across Japan (JDDM 22).
    Oishi M; Yokoyama H; Abe N; Iwasaki K; Okuguchi F; Kawai K; Sugimto H; Takamura H; Takeda H; Doi K; Hirao K; Ikeda S
    Jpn Clin Med; 2011; 2():43-51. PubMed ID: 23885190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time and cost involved in the care of newly registered patients with diabetes mellitus and other lifestyle diseases at diabetes clinics in Japan (JDDM 4).
    Oishi M; Yokoyama H; Abe N; Iwasaki K; Okuguchi F; Kawai K; Sugimoto H; Takamura H; Takeda H; Doi K; Hirao K; Ikeda S
    Diabet Med; 2007 Oct; 24(10):1149-55. PubMed ID: 17888135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
    Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
    Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of one-year insulin glargine and insulin glulisine basal-bolus treatment in people with type 2 diabetes. An analysis from drug reimbursement perspective].
    Jermendy G; Kovács G
    Orv Hetil; 2018 Dec; 159(50):2122-2128. PubMed ID: 30545262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.
    Furler J; O'Neal D; Speight J; Blackberry I; Manski-Nankervis JA; Thuraisingam S; de La Rue K; Ginnivan L; Doyle R; Holmes-Truscott E; Khunti K; Dalziel K; Chiang J; Audehm R; Kennedy M; Clark M; Jenkins A; Lake AJ; Januszewski AS; Catchpool M; Liew D; Clarke P; Best J
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):17-26. PubMed ID: 31862147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
    Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
    J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China.
    Liu G; Dou J; Pan Y; Yan Y; Zhu H; Lu J; Gaisano H; Ji L; He Y
    Front Endocrinol (Lausanne); 2018; 9():639. PubMed ID: 30420835
    [No Abstract]   [Full Text] [Related]  

  • 11. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
    Sato M; Ye W; Sugihara T; Isaka Y
    BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initiating insulin therapy in patients with diabetes mellitus type 2: in a transmural setting is at least as effective as in an outpatient setting; a retrospective study with a 4-year follow-up].
    Rosendal H; Vondeling H; de Witte LP; Hutubessy RC; van Beekum WT; Heine RJ
    Ned Tijdschr Geneeskd; 2002 Jan; 146(4):166-71. PubMed ID: 11845567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lifestyle education program for type 2 diabetes patients in clinics: study design of a cluster randomized trial.
    Adachi M; Yamaoka K; Watanabe M; Nishikawa M; Hida E; Kobayashi I; Tango T
    BMC Public Health; 2010 Nov; 10():742. PubMed ID: 21118514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct healthcare costs and clinical outcomes after insulin initiation in patients with type 2 diabetes mellitus in Spain: 24-month follow-up data from the INSTIGATE study.
    Dilla T; Nicolay C; Alvarez M; Reviriego J; Goday A; Castell C
    Endocrinol Nutr; 2013 May; 60(5):224-34. PubMed ID: 23528647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus.
    Lechleitner M; Roden M; Haehling E; Mueller M
    Wien Klin Wochenschr; 2005 Sep; 117(17):593-8. PubMed ID: 16395988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.